MXPA03000252A - Derivados de quinolina que tienen actividad de inhibicion de fcev. - Google Patents
Derivados de quinolina que tienen actividad de inhibicion de fcev.Info
- Publication number
- MXPA03000252A MXPA03000252A MXPA03000252A MXPA03000252A MXPA03000252A MX PA03000252 A MXPA03000252 A MX PA03000252A MX PA03000252 A MXPA03000252 A MX PA03000252A MX PA03000252 A MXPA03000252 A MX PA03000252A MX PA03000252 A MXPA03000252 A MX PA03000252A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- compounds
- integer
- inhibiting activity
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invencion se refiere a los compuestos de la formula (I) en donde cualquiera de uno de G1, G2, G3, G4, y G5, es nitrogeno y los otros cuatro son -CH-, o G1, G2, G3, G4, y G5, son todos -CH; Z es -O-, -NH-, -S- o -CH2- o un enlace directo; Z se enlaza a cualquiera de uno de G1, G2, G3, y G4; n es un entero de 0 a 5; m es un entero de 0 a 3; Ra representa hidrogeno o fl°or; Rb, R1 y R2 son como se han definido en la presente y una sal del mismo, procedimiento para la preparacion de tales compuestos, las composiciones farmacéuticas que contienen un compuesto de la formula I o una sal farmacéuticamente aceptable del mismo, como un ingrediente activo, y el uso de un compuesto de la formula I en la obtencion de un medicamento para la produccion de un efecto antiangiogénico y/o de la reduccion de la permeabilidad vascular en animales de sangre caliente. Los compuestos de la formula I y las sales farmacéuticamente aceptables del mismo inhiben los efectos de FCEV, una propiedad del valor en el tratamiento de un n°mero de estados de enfermedades incluyendo el cáncer y la artritis reumatoide.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00402254 | 2000-08-09 | ||
| PCT/GB2001/003553 WO2002012226A1 (en) | 2000-08-09 | 2001-08-08 | Quinoline derivatives having vegf inhibiting activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03000252A true MXPA03000252A (es) | 2003-06-06 |
Family
ID=8173805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03000252A MXPA03000252A (es) | 2000-08-09 | 2001-08-08 | Derivados de quinolina que tienen actividad de inhibicion de fcev. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7371765B2 (es) |
| EP (1) | EP1313726A1 (es) |
| JP (1) | JP2004505964A (es) |
| KR (1) | KR20030036686A (es) |
| CN (1) | CN1315822C (es) |
| AU (2) | AU2001276536B2 (es) |
| BR (1) | BR0113056A (es) |
| CA (1) | CA2415469A1 (es) |
| IL (2) | IL153947A0 (es) |
| MX (1) | MXPA03000252A (es) |
| NO (1) | NO326315B1 (es) |
| NZ (1) | NZ523358A (es) |
| WO (1) | WO2002012226A1 (es) |
| ZA (1) | ZA200300217B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1553097E (pt) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogénese e seus intermediários |
| BRPI0015203B8 (pt) * | 1999-11-05 | 2021-05-25 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, e, uso de um composto |
| EP1272185B1 (en) | 2000-03-06 | 2005-07-27 | AstraZeneca AB | Use of quinazoline derivatives as angiogenesis inhibitors |
| SI1274692T1 (sl) * | 2000-04-07 | 2006-12-31 | Astrazeneca Ab | Kinazolinske spojine |
| RU2362774C1 (ru) * | 2002-02-01 | 2009-07-27 | Астразенека Аб | Хиназолиновые соединения |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| AU2008202205B2 (en) * | 2003-12-23 | 2009-09-10 | Pfizer Inc. | Novel quinoline derivatives |
| SG141459A1 (en) * | 2003-12-23 | 2008-04-28 | Pfizer | Novel quinoline derivatives |
| JP4585978B2 (ja) * | 2005-03-03 | 2010-11-24 | 参天製薬株式会社 | キノリルアルキルチオ基を有する新規環式化合物 |
| WO2007017740A1 (en) | 2005-08-08 | 2007-02-15 | Pfizer Inc. | Salts and polymorphs of a vergf-r inhibitor |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| JP2011526892A (ja) | 2008-06-30 | 2011-10-20 | アンジオブラスト システムズ，インコーポレーテッド | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
| CN101723894B (zh) * | 2009-12-03 | 2011-12-28 | 南京大学 | N-喹啉酰胺类衍生物及其制法与用途 |
| US9604963B2 (en) | 2011-03-04 | 2017-03-28 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN105189462B (zh) | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| AU2014220300B2 (en) | 2013-02-21 | 2016-10-13 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
| CA2928658A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2016161952A1 (zh) * | 2015-04-07 | 2016-10-13 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
| AU2017217677A1 (en) | 2016-02-08 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
| CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3931189A4 (en) | 2019-02-27 | 2022-11-30 | The Regents Of The University Of California | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS |
| EP4091613A4 (en) * | 2020-01-19 | 2024-02-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | QUINOLINE DERIVATIVE FOR TREATING RHEUMATOID ARTHRITIS |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US36256A (en) * | 1862-08-19 | Improvement in sewing-m ach ines | ||
| US3755332A (en) | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| JP4009681B2 (ja) * | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| KR100567649B1 (ko) * | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| ES2351684T3 (es) | 1996-10-01 | 2011-02-09 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| WO1998054093A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| NZ510551A (en) * | 1998-09-29 | 2003-03-28 | American Cyanamid Co | Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
-
2001
- 2001-08-08 NZ NZ523358A patent/NZ523358A/en unknown
- 2001-08-08 EP EP01954192A patent/EP1313726A1/en not_active Withdrawn
- 2001-08-08 JP JP2002518201A patent/JP2004505964A/ja active Pending
- 2001-08-08 CN CNB018139000A patent/CN1315822C/zh not_active Expired - Fee Related
- 2001-08-08 BR BR0113056-0A patent/BR0113056A/pt not_active Application Discontinuation
- 2001-08-08 IL IL15394701A patent/IL153947A0/xx unknown
- 2001-08-08 AU AU2001276536A patent/AU2001276536B2/en not_active Ceased
- 2001-08-08 AU AU7653601A patent/AU7653601A/xx active Pending
- 2001-08-08 CA CA002415469A patent/CA2415469A1/en not_active Abandoned
- 2001-08-08 KR KR10-2003-7001934A patent/KR20030036686A/ko active IP Right Grant
- 2001-08-08 MX MXPA03000252A patent/MXPA03000252A/es not_active Application Discontinuation
- 2001-08-08 US US10/332,274 patent/US7371765B2/en not_active Expired - Fee Related
- 2001-08-08 WO PCT/GB2001/003553 patent/WO2002012226A1/en active IP Right Grant
-
2003
- 2003-01-08 ZA ZA200300217A patent/ZA200300217B/en unknown
- 2003-01-14 IL IL153947A patent/IL153947A/en not_active IP Right Cessation
- 2003-02-07 NO NO20030625A patent/NO326315B1/no not_active IP Right Cessation
-
2007
- 2007-11-29 US US11/947,533 patent/US20080312273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002012226A1 (en) | 2002-02-14 |
| KR20030036686A (ko) | 2003-05-09 |
| CN1315822C (zh) | 2007-05-16 |
| IL153947A0 (en) | 2003-07-31 |
| AU2001276536B9 (en) | 2002-02-18 |
| US7371765B2 (en) | 2008-05-13 |
| AU7653601A (en) | 2002-02-18 |
| AU2001276536B2 (en) | 2007-01-04 |
| ZA200300217B (en) | 2004-04-08 |
| JP2004505964A (ja) | 2004-02-26 |
| NO20030625D0 (no) | 2003-02-07 |
| BR0113056A (pt) | 2003-07-08 |
| NZ523358A (en) | 2004-09-24 |
| NO326315B1 (no) | 2008-11-10 |
| CA2415469A1 (en) | 2002-02-14 |
| EP1313726A1 (en) | 2003-05-28 |
| US20080312273A1 (en) | 2008-12-18 |
| NO20030625L (no) | 2003-02-07 |
| CN1446212A (zh) | 2003-10-01 |
| IL153947A (en) | 2008-12-29 |
| US20030199491A1 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03000252A (es) | Derivados de quinolina que tienen actividad de inhibicion de fcev. | |
| TR199801530T2 (xx) | VEGF �nhibit�rleri olarak kinazolin t�revleri. | |
| AU4313797A (en) | Qinoline derivatives inhibiting the effect of growth factors such as vegf | |
| TR199801115T2 (xx) | Kinazolin t�revleri. | |
| MY144042A (en) | Quinazoline compounds | |
| MY129540A (en) | Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect | |
| MXPA05001581A (es) | Algunas imidazopiridinas novedosas y su uso. | |
| CA2344290A1 (en) | Quinazoline derivatives | |
| UA72946C2 (uk) | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| GB9914486D0 (en) | Medicaments | |
| AU7652101A (en) | Cinnoline compounds | |
| HUT67289A (en) | Benzimidazole and pyridoimidazole derivatives, pharmaceutical compositions containing them and process for their production | |
| SE9901573D0 (sv) | New compounds | |
| WO2002012227A3 (en) | Indole, azaindole and indazole derivatives having vegf inhibiting activity | |
| IL97892A0 (en) | 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidin-4-ones,their preparation and pharmaceutical compositions containing them | |
| AP2004003160A0 (en) | Tolterodine salts | |
| HUT65983A (en) | Process for the production of imidazole-condensed-compounds and pharmaceutical compositions containing them | |
| SE0002476D0 (sv) | New compounds | |
| UA72945C2 (uk) | Сполука (варіанти), фармацевтична композиція, спосіб лікування (варіанти) | |
| DE60123827D1 (en) | 1-methylcarbapenemderivate | |
| SE9901572D0 (sv) | New compounds | |
| MY160429A (en) | 2, 5-disubstituted 3-mercaptopentanoic acid | |
| MX9605376A (es) | Derivados novedosos de acido hidroximico, composiciones farmaceuticas que los contienen y procesos para preparar los mismos. | |
| PL349220A1 (en) | Heterocyclic derivatives as inhibitors of factor xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |